logo

Articles scientifiques (5 dernières années)

Google Scholar
Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States Ann Intern Med doi:10.7326/M24-0421 Laprise JF, Chesson HW, Markowitz LE, Drolet M, Brisson M
Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling J Natl Cancer Inst Monogr. 2024;2024(67):387-99 Brisson M, Laprise JF, Drolet M, Chamberland E, Benard E, Burger EA, Jit M, Kim JJ, Markowitz LE, Sauvageau C, Sy S
Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting J Natl Cancer Inst Monogr. 2024;2024(67):379-86 Burger EA, Laprise JF, Portnoy A, Spencer JC, Sy S, Regan MC, Benard E, Drolet M, Brisson M, Kim JJ
Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis. CMAJ 2024;196(33):E1136-E1143 Drolet M, Laprise JF, Chamberland E, Sauvageau C, Wilson S, Lim GH, Ogilvie G, Tuite A, Brisson M
Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries EClinicalMedicine 2024 Jul 18:74:102735 Prem K, Cernuschi T, Malvolti S, Brisson M, Jit M
Population immunity to varicella in Canada: A Canadian Immunization Research Network (CIRN) study PLoS One. 2024;19(8):e0309154 Wright J, Crowcroft N, McLachlan E, Perez-Iratxeta C, Joh E, Osman S. Hatchette T, Deeks SL, Wilson SE, Hughes SL, Halperin SA, Buchan SA, Ward BJ, Gubbay J, Brisson M, Serhir B, Severini A, Bolotin S
Association of naturally acquired type-specific HPV antibodies and subsequent HPV re-detection: systematic review and meta-analysis Infect Agents Cancer 2023;18:70. https://doi.org/10.1186/s13027-023-00546-3 Yokoji K, Giguère K, Malagón T, Rönn MM, Mayaud P, Kelly H, Delany-Moretlwe S, Drolet M, Brisson M, Boily MC, Maheu-Giroux M
Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis Lancet PH 2023;8(10):e788-e799. https://doi.org/10.1016/S2468-2667(23)00180-9 Bénard É, Drolet M, Laprise JF, Gingras G, Jit M, Boily MC, Bloem P, Brisson M
Global impact and cost‑effectiveness of one‑dose versus two‑dose human papillomavirus vaccination schedules: a comparative modelling analysis BMC Med 2023;21(313). https://doi.org/10.1186/s12916-023-02988-3 Prem K, Choi YH, Bénard É, Burger EA, Hadley L, Laprise JF, Regan MC, Drolet M, Sy S, Abbas K, Portnoy A, Kim JJ, Brisson M, Jit M
Regional and country-level trends in cervical cancer screening coverage in sub-Saharan Africa: A systematic analysis of population-based surveys (2000–2020) PLoS medicine 2023;20(1):e1004143 Yang L, Boily MC, Rönn MM, Obiri-Yeboah D, Morhason-Bello I, Meda N, Lompo O, Mayaud P, Pickles M, Brisson M, Hodgins C, Delany-Moretlwe S, Maheu-Giroux M
Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis Lancet Global Health 2023;11(1):e48-58. Bénard E, Drolet M, Laprise JF, Jit M, Prem K, Boily MC, Brisson M
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study The Lancet ID 2023;23(1):45-55. https://doi.org/10.1016/S1473-3099(22)00578-3. Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G
Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening eClinicalMedicine 2022, Nov. 17;101754 https://doi.org/10.1016/j.eclinm.2022.101754 Boily MC, Barnabas RV, Rönn MM, Bayer CJ, Schalkwyk C, Sonia N, Rao DW, Staadegaard L, Liu G, Silhol R, Brisson M, Johnson LF, Bloem P, Gottlieb S, Broutet N, Dalal S
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada Clinical Infectious Diseases 2022;75(11):1980–1992 Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G, Galanis E, Fjell CD, Sbihi H, Fortin E, Barkati S, Sauvageau C, Naus M, Patrick DM, Henry B, Hoang LMN, De Wals P, Garenc C, Carignan A, Drolet M, Jassem AN, Sadarangani M, Brisson M, Krajden M, De Serres G
Prevalence and risk factors for human papillomavirus infection among female sex workers in Hanoi and Ho Chi Minh City, Viet Nam: a cross-sectional study – Prevalence and risk factors for HPV among FSWs in Viet Nam Western Pac Surveill Response J 2022;13(4):1-11. doi: 10.5365/wpsar.2022.13.4.894 Pham QD, Prem K, Le TA, Trang NV, Jit M, Nguyen TA, Cao V, Le-Ha TD, Chu MTN, Le LTK, Toh ZQ, Brisson M, Garland S, Murray G, Bright K, Dang DA, Tran HP, Mulholland EK
Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis eClinicalMedicine 2022;52:101585 https://doi.org/10.1016/j.eclinm.2022.101585 Staadegaard L, Rönn MM, Soni N, Bellerose ME, Bloem P, Brisson M, Maheu-Giroux M, Barnabas RV, Drolet M, Mayaud P, Dalal S, Boily MC
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada JAMA Netw Open. 2022;5(10):e2236670. doi:10.1001/jamanetworkopen.2022.36670 Carazo S, Skowronski DM, Brisson, M
Letter to the Editor: Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions Vaccine 2022 https://doi.org/10.1016/j.vaccine.2022.07.022 Burger E, Baussano I, Kim JJ, Laprise JF, Berkhof J, Schiller JT, Canfell K, Prem K, Brisson M, Jit M, Barnabas RV
Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs Vaccine 2022;S0264-410X(22)00834-9. doi: 10.1016/j.vaccine.2022.06.065. Online ahead of print. Markowitz LE, Drolet M, Lewis RM, Lemieux-Mellouki P, Pérez N, Jit M, Brotherton JM, Ogilvie, G Kreimer AR, Brisson M
Review of the current published evidence on single-dose HPV vaccination 4th Edition PATH. May 2022. Single dose HPV vaccine evaluation consortium
Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic BMC Medicine (2022) 20:199. https://doi.org/10.1186/s12916-022-02398-x Godbout A, Drolet M, Mondor M, Simard M, Sauvageau C, De Serres G, Brisson M
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study BMC Public Health 2022;22:1032. https://doi.org/10.1186/s12889-022-13402-7 Drolet M, Godbout A, Mondor M, Béraud G, Drolet-Roy L, Lemieux-Mellouki P, Bureau A, Demers É, Boily MC, Sauvageau C, De Serres G, Hens N, Beutels P, Dervaux B, Brisson M
Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting Int J Cancer 2022. doi:10.1002/ijc.34054. Online ahead of print. Burger EA, Laprise JF, Sy S, Regan MC, Prem K, Jit M, Brisson M, Kim JJ
Mortality trends and length of stays among hospitalized patients with COVID-19 in Ontario and Québec (Canada): a population-based cohort study of the first three epidemic waves Int J Infect Dis 2022;121:1-10. doi:10.1016/j.ijid.2022.04.048. Online ahead of print Xia Y, Ma H, Buckeridge DL, Brisson M, Sander B, Chan A, Verma A, Ganser I, Kronfli N, Mishra S, Maheu-Giroux M
Population immunity to measles in Canada using Canadian Health Measures survey data – A Canadian Immunization Research Network (CIRN) study Vaccine 2022;40(23):3228-35. doi: 10.1016/j.vaccine.2022.04.011. Epub 2022 Apr 28 Osman S, Crowcroft N, McLachlan E, Hatchette T, Pere-Iratxeta C, Joh E, Wright J, Halperin SA, Deeks S, Wilson S, Buchan S, Ward B, Gubbay J, Brisson M, Serhir B, Severini A, Bolotin S
Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada Clin Infect Dis . 2021 Aug 30;ciab739. doi: 10.1093/cid/ciab739. Online ahead of print Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, Brousseau N, Drolet M, Ouakki M, Sauvageau C, Barkati S, Fortin E, Carignan A, De Wals P, Skowronski DM, De Serres G
Potential Benefit of Extended Dose Schedules of Human Papillomavirus (HPV) Vaccination in the Context of Limited Resources and COVID-19 Disruptions in Low- and Middle-Income Countries: A Mathematical Modeling Analysis. Preprint available at SSRN 4016646, 2021 Bénard E, Drolet M, Laprise JF, Jit M, Prem K, Boily MC, Brisson MC
Geographic concentration of SARS-CoV-2 cases by social determinants of health in metropolitan areas in Canada: a cross-sectional study CMAJ 2022;194(6):E195-E204. doi: 10.1503/cmaj.211249 Xia Y, Ma H, Moloney G, Velásquez García HA, Sirski M, Janjua NZ, Vickers D, Williamson T, Katz A, Yiu K, Kustra R, Buckeridge DL, Brisson M, Baral SD, Mishra S, Maheu-Giroux M
Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam Int J Infect Dis . 2021 Nov;112:136-143. doi: 10.1016/j.ijid.2021.09.016 Tuan LA, Prem K, Pham QD, Toh ZQ, Tran HP, Nguyen PD, Mai CTN, Ly LTK, Cao V, Le-Ha TD, Tuan NA, Jit M, Bright K, Brisson M, Nguyen TV, Garland S, Anh DD, Trang NV, Mulholland K
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study MedRxiv doi: https://doi.org/10.1101/2021.10.06.21264632 Drolet M, Godbout A, Mondor M, Drolet-Roy L, Beraud G, Lemmieux-Mellouki P, Demers E, Boily MC, Sauvageau C, De Serres G, Hens N, Beutels P, Dervaux B, Brisson M
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis Lancet Infect Dis 2021. doi: https://doi.org/10.1016/S1473-3099(20)30860-4 Drolet M, Laprise JF, Martin D, Jit M, Bénard É, Gingras G, Boily MC, Alary M, Baussano I, Hutubessy R, Brisson M
Assessing fitness-for-purpose and comparing the suitability of COVID-19 multi-country models for local contexts and users Gates Open Research 2021;5(79):79 Clapham H, Gad M, Gheorghe A, Hutubessy R, Megiddo I, Painter C, Ruiz F, Cheikh N, Gorgens M, Wilkinson T, Brisson M, Gay N, Labadin J, McVernon J, Luz PM, Ndifon W, Nichols BE, Prinja S, Salomon J, Tshangela A
Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019 Vaccine. 2021;39(28):3756-3766. doi: 10.1016/j.vaccine.2021.05.031. Epub 2021 May 29. Grewal R, Deeks SL, Hart TA, Coxh J, De Pokomandy A, Grennan T, Lambert G, Moore D, Brisson M, Coutlée F, Gaspar M, George C, Grace D, Jollimore J, Lachowsky NJ, Nisenbauma R, Ogilvie G, Sauvageau C, Burchell AN
From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness Prev Med. 2021;144:106354 Jit M, Prem K, Benard E, Brisson M
The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018 Sex Transm Dis. 2021 Apr 1;48(4):278-284 Chesson HW, Laprise JF, Brisson M, Martin D, Ekwueme DU, Markowitz LE.
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis MedRxiv Prem K, Choi YH, Bénard E, Burger EA, Hadley L, Laprise JF, Regan C, Drolet M, Sy S, Abbas K, Kim JJ, Brisson M, Jit M
The role of case importation in explaining differences in early SARS-CoV-2 transmission dynamics in Canada – A mathematical modeling study of surveillance data Int J Inf Dis 2021;102:254-9. doi: 10.1016/j.ijid.2020.10.046 Godin A, Xia Y, Buckeridge DL, Mishra S, Douwes-Schultz D, Shen Y, Lavigne M, Drolet M, Schmidt AM, Brisson M, Maheu-Giroux M
Estimated prevalence and incidence of disease-associated HPV types among 15-59-year-olds in the United States Sex Transm Dis 2021; Volume Publish Ahead of Print - doi: 10.1097/OLQ.0000000000001356 Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson H, Brisson M, Markowitz LE
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study The Lancet 2021;397(10272):398-408. doi: 10.1016/S0140-6736(20)32657-X Li X, Mukandavire C, Cucunubá ZM, Londono SE, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, et al.
Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study Lancet Infect Dis 2021;21(1):116-126. doi: 10.1016/S1473-3099(20)30277-2 Greenaway C, Greenwald ZR, Akaberi A, Song S, Passos-Castilho AM, Chakra CNA, Palayew A, Alabdulkarim B, Platt R, Azoulay L, Brisson M, Quach C
The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018 Sexually Transmitted Diseases 2021;;48(4):215-21 Chesson HW, Spicknall IH, Bingham A, Brisson M, Eppink ST, Farnham PG, Kreisel KM, Kumar S, Laprise JF, Peterman TA, Roberts H, Gift TL
Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule Vaccine. Available online 13 January 2021. https://doi.org/10.1016/j.vaccine.2020.12.031 Whitworth HS, Schiller J, Markowitz LE, Jit M, Brisson M, Simpson E, Watson-Jones D
Mortality reductions and lives saved on the path to eliminating cervical cancer in 78 Low and Lower-Middle Income Countries: Comparative modelling of impact of achieving WHO targets for scaling up vaccination, cervical screening and cancer treatment services The Lancet 2020. https://doi.org/10.1016/S0140-6736(20)30157-4 Canfell K, Kim J, Brisson M, Keane A, Simms K, Caruana M, Burger E, Martin D, Nguyen DTN, Benard É, Sy S, Regan C, Laprise JF, Torode J, Smith M, Fidarova E, Trapani D, Ilbawi A, Broutet N, Hutubessy R
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet 2020. https://doi.org/10.1016/S0140-6736(20)30068-4 Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R.
Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study Lancet Glob Health 2020. doi: 10.1016/S2214-109X(20)30022-X. [Epub ahead of print] Abbas KM, van Zandvoort K, Brisson M, Jit M
Review of the current published evidence for single-dose HPV vaccination: White Paper RHO Cervical Cancer Library Single-Dose HPV Vaccine Evaluation Consortium
Modelling multi-site transmission of the human papillomavirus and its impact on vaccination effectiveness Lemieux-Mellouki P, Drolet M, Jit M, Gingras G, Brisson M Epidemics 2017Dec;21:80-87. doi: 10.1016/j.epidem.2017.08.001.
Review of the current published evidence for single-dose HPV vaccination 2nd Edition: White Paper RHO Cervical Cancer Library Single-Dose HPV Vaccine Evaluation Consortium
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis The Lancet 2019;DOI: https://doi.org/10.1016/S0140-6736(19)30298-3 Drolet M, Bénard E, Pérez N, Brisson M, the HPV Vaccination Impact Study Group
Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study Hum Vaccin Immunother. 2019 Jul 16:1-9. doi: 10.1080/21645515.2019.1619402 Bolotin S, Severini A, Hatchette T, McLachlan E, Savage R, Hughes SL, Wang J, Deeks SL, Wilson S, Brisson M, Halperin SA, Gubbay J, Mazzulli T, Serhir B, Ward BJ, Crowcroft N
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool Vaccine. 2019 Jul 18;37(31):4376-4381. doi: 10.1016/j.vaccine.2019.06.019. Epub 2019 Jun 24 Bellan SE, Eggo RM, Gsell PS, Kucharski AJ, Dean NE, Donohue R, Zook M, Edmunds WJ, Odhiambo F, Longini IM Jr, Brisson M, Mahon BE, Henao-Restrepo AM
Guidelines for multi-model comparisons of the impact of infectious disease interventions BMC Med. 2019 Aug 19;17(1):163. doi: 10.1186/s12916-019-1403-9 den Boon S, Jit M, Brisson M, Medley G, Beutels P, White R, Flasche S, Hollingsworth TD, Garske T, Pitzer VE, Hoogendoorn M, Geffen O, Clark A, Kim J, Hutubessy R
Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study CMAJ August 26, 2019 191 (34) E932-E939; DOI: https://doi.org/10.1503/cmaj.190274 Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M
HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control Papillomavirus research, ISSN: 2405-8521, Vol: 8 (2019), Page: 100184 Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, Campos N, Jennett C, Sharma M, Simms KT, Smith MA, Velentzis LS, Brisson M, Jit M
Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States Ann Intern Med. 2019 Dec 10. doi: 10.7326/M19-1182. [Epub ahead of print] Laprise JF, Chesson HW, Markowitz LE, Drolet M, Martin D, Bénard É, Brisson M.
Global elimination of cervical cancer as a public health problem The Lancet Oncology 2019 Mar;20(3):319-321. doi: 10.1016/S1470-2045(19)30072-5. Brisson M, Drolet M